- Home
- CHRS
as 12-20-2024 2:33pm EST
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 185.5M | IPO Year: | 2014 |
| Target Price: | $5.38 | AVG Volume (30 days): | 10.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $3.70 | Next Earning Date: | 11-06-2024 |
| Revenue: | $304,340,000 | Revenue Growth: | 44.19% |
| Revenue Growth (this year): | 1.64% | Revenue Growth (next year): | 16.98% |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
MT Newswires
19 days ago
Sector Update: Health Care Stocks Decline Premarket Tuesday
MT Newswires
19 days ago
Sector Update: Health Care
MT Newswires
19 days ago
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
GlobeNewswire
19 days ago
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
BioPharma Dive
19 days ago
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M
GlobeNewswire
25 days ago
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
Thomson Reuters StreetEvents
a month ago
Q3 2024 Coherus BioSciences Inc Earnings Call
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.